248 related articles for article (PubMed ID: 22971493)
1. Switching to an L/N-type calcium channel blocker shows renoprotective effects in patients with chronic kidney disease: the Kyoto Cilnidipine Study.
Hatta T; Takeda K; Shiotsu Y; Sugishita C; Adachi T; Kimura T; Sonomura K; Kusaba T; Kishimioto N; Narumiya H; Tanda S; Tamagaki K; Yamada K; Kameyama H; Kido H; Harada S; Bito Y; Moriguchi J; Morimoto S; Okigaki M; Itoh H; Mori Y; Nakata T; Maki K; Sasaki S; Sawada K; Matsubara H
J Int Med Res; 2012; 40(4):1417-28. PubMed ID: 22971493
[TBL] [Abstract][Full Text] [Related]
2. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
Fujita T; Ando K; Nishimura H; Ideura T; Yasuda G; Isshiki M; Takahashi K;
Kidney Int; 2007 Dec; 72(12):1543-9. PubMed ID: 17943080
[TBL] [Abstract][Full Text] [Related]
3. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.
Kanaoka T; Tamura K; Wakui H; Ohsawa M; Azushima K; Uneda K; Kobayashi R; Fujikawa T; Tsurumi-Ikeya Y; Maeda A; Yanagi M; Toya Y; Umemura S
Int J Mol Sci; 2013 Aug; 14(8):16866-81. PubMed ID: 23959116
[TBL] [Abstract][Full Text] [Related]
4. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
[TBL] [Abstract][Full Text] [Related]
5. Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Fukumoto S; Ishimura E; Motoyama K; Morioka T; Kimoto E; Wakikawa K; Shoji S; Koyama H; Shoji T; Emoto M; Nishizawa Y; Inaba M;
Diabetes Res Clin Pract; 2012 Jul; 97(1):91-8. PubMed ID: 22336632
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
[TBL] [Abstract][Full Text] [Related]
7. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H;
Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
[TBL] [Abstract][Full Text] [Related]
8. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.
Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1027-37. PubMed ID: 20649501
[TBL] [Abstract][Full Text] [Related]
9. Cilnidipine: Next Generation Calcium Channel Blocker.
Shete MM
J Assoc Physicians India; 2016 Apr; 64(4):95-99. PubMed ID: 27734656
[TBL] [Abstract][Full Text] [Related]
10. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
11. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases.
Kojima S; Shida M; Yokoyama H
Hypertens Res; 2004 Jun; 27(6):379-85. PubMed ID: 15253102
[TBL] [Abstract][Full Text] [Related]
12. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
Moore KH; Clemmer JS
Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
[TBL] [Abstract][Full Text] [Related]
13. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M
Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
[TBL] [Abstract][Full Text] [Related]
14. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.
Konda T; Enomoto A; Matsushita J; Takahara A; Moriyama T
Nephron Physiol; 2005; 101(1):p1-13. PubMed ID: 15886499
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Ando K; Ueshima K; Tanaka S; Kosugi S; Sato T; Matsuoka H; Nakao K; Fujita T
Int J Med Sci; 2013; 10(9):1209-16. PubMed ID: 23935398
[TBL] [Abstract][Full Text] [Related]
16. Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis.
Thamcharoen N; Susantitaphong P; Wongrakpanich S; Chongsathidkiet P; Tantrachoti P; Pitukweerakul S; Avihingsanon Y; Praditpornsilpa K; Jaber BL; Eiam-Ong S
Hypertens Res; 2015 Dec; 38(12):847-55. PubMed ID: 26134125
[TBL] [Abstract][Full Text] [Related]
17. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
Miwa Y; Tsuchihashi T; Ohta Y; Tominaga M; Kawano Y; Sasaguri T; Ueno M; Matsuoka H
Clin Exp Hypertens; 2010; 32(6):400-5. PubMed ID: 20828221
[TBL] [Abstract][Full Text] [Related]
18. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine.
Seino H; Miyaguchi S; Yamazaki T; Ota S; Yabe R; Suzuki S
Arzneimittelforschung; 2007; 57(8):526-31. PubMed ID: 17915639
[TBL] [Abstract][Full Text] [Related]
19. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Aritomi S; Niinuma K; Ogawa T; Konda T; Nitta K
Clin Exp Nephrol; 2013 Feb; 17(1):41-50. PubMed ID: 23011292
[TBL] [Abstract][Full Text] [Related]
20. Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and aldosterone levels.
Tanaka M; Sekioka R; Nishimura T; Ichihara A; Itoh H
Diabetes Res Clin Pract; 2014 Dec; 106(3):504-10. PubMed ID: 25458339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
